Guidance and quality standards awaiting development | Guidance

Showing 181 to 190 of 360

Guidance and quality standards awaiting development
Title	Type
Mezigdomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatment lines [TSID12402]	Technology appraisal guidance
Miniature lens system implantation for advanced age-related macular degeneration	HealthTech guidance
MK-3000 for treating diabetic macular oedema [TSID12422]	Technology appraisal guidance
Mosunetuzumab with lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6655]	Technology appraisal guidance
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]	Technology appraisal guidance
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]	Technology appraisal guidance
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]	Technology appraisal guidance
Nemtabrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma without a 17p deletion or TP53 mutation	Technology appraisal guidance
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]	Technology appraisal guidance
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping [TSID10593]	Technology appraisal guidance